[Lab] 24th independent test on QSC — 98.4% on a claimed 98.0%, and the trend is the interesting part
Short version of the title, which is already short: 24th independent test on QSC — 98.4% on a claimed 98.0%, and the trend is the interesting part. Longer version underneath. Since the title puts numbers in the shop window: 98.4% and 98.0%. The honest evidence position, written out so this board does not drift. Phase…
Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing.
read the histology endpoint definitions before quoting a response rate
That figure is from the obesity programme, and this thread is about the hepatic one.
It is a dual agonist at the GLP-1 and glucagon receptors. The glucagon arm is associated with increased energy expenditure and with effects on hepatic fat, which is why the development programme is oriented towards liver disease.
[removed by moderator]
a liver endpoint is not a weight endpoint with better marketing
Careful with the mechanism claim. Glucagon agonism is plausible as an explanation and it has not been isolated as the operative one.
It is a dual agonist at the GLP-1 and glucagon receptors.
Adding the standing caveat — unapproved compound, research material is not for human use.
That is an escalation schedule for an unapproved compound and this board does not host those.
Read the phase 2 hepatic paper properly and the endpoint definitions were more interesting than the headline response rate.